VYNE Therapeutics Details Reverse Merger with Yarrow Bioscience, $100M Financing, Cash Dividend, and Reverse Stock Split

summarizeSummary

VYNE Therapeutics is proceeding with its reverse merger into Yarrow Bioscience, which includes a $100 million pre-closing financing for Yarrow, a cash dividend of $14.5M-$16.5M for existing VYNE shareholders, and a proposed reverse stock split to maintain Nasdaq listing. Existing VYNE shareholders will own approximately 3.0% of the combined company.

check_boxKey Events

• Reverse Merger with Yarrow Bioscience

  VYNE Therapeutics will merge with Yarrow Bioscience, with Yarrow surviving as a wholly-owned subsidiary. The combined company will be renamed 'Yarrow Bioscience, Inc.' and is expected to trade under 'YARW' on Nasdaq.

• Significant Dilution for VYNE Shareholders

  Existing VYNE securityholders are expected to own approximately 3.0% of the outstanding shares of the combined company on a fully-diluted basis, while former Yarrow securityholders (including new investors) will own approximately 97.0%.

• $100 Million Pre-Closing Financing

  Yarrow has secured commitments for a $100 million private placement, which will fund the combined company's operations immediately prior to the merger closing.

• Cash Dividend to Existing Shareholders

  VYNE expects to pay a special cash dividend of approximately $14.5 million to $16.5 million to its existing shareholders prior to the merger closing.

auto_awesomeAnalysis

This 424B3 filing provides final details for the previously announced reverse merger between VYNE Therapeutics and Yarrow Bioscience, a critical strategic pivot for VYNE following recent clinical trial setbacks and Nasdaq non-compliance. While existing VYNE shareholders will receive a substantial cash dividend of $14.5M-$16.5M, they will experience significant dilution, owning only about 3.0% of the combined entity. The merger is contingent on shareholder approval of a reverse stock split (1-for-10 to 1-for-70) and an authorized share increase, both necessary to maintain Nasdaq listing and facilitate future capital raises. The combined company will be primarily focused on advancing Yarrow's clinical-stage pipeline, backed by a $100 million pre-closing financing. This transaction effectively transforms VYNE into a new entity with a new strategic direction and management, offering a path forward from its previous challenges.